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Abstract 
Four modified cytochrome b’s carrying mononucleotide substitutions affecting center N residues were analysed. The mutant carrying a G33D 
change does not incorporate heme into the apocytochrome b and fails to grow on non-fermentable carbon sources. Out of 85 genetically independent 
revertants derived from this mutant, 82 were true back-mutants restoring the wild type sequence (D33G). The remaining three replaced the aspartic 
acid by an alanine (D33A) indicating that small size residues are best tolerated at this position which is consistent with the perfect conservation of 
the G33 during evolution. This glycine may be of crucial importance for helix packing around the hemes. The replacement of methionine at position 
221 by lysine (M221K) produced a non-functional cytochrome b [(1993) J. Biol. Chem. 268,1562615632]. Non-native revertants replacing the lysine 
221 by glutamic acid (K221E) or glutamine (K221Q) expressed a selective resistance to antimycin and antimycin derivatives having a modified 
dilactone ring moiety. Cytochrome b residues in 33 and in 221 seemed to contribute to the quinone reduction (QN) site of the cytochrome bc, complex. 
Possible intramolecular interactions between the N-terminal region and the loop connecting helices IV and V of cytochrome b are proposed. 
Key words: Mitochondrial cytochrome b; Respiratory deficiency mutation; Non-native reversion; Antimycin resistance; Saccharomy- 
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1. Introduction 
In the mitochondrial respiratory chain, the cyto- 
chrome bc, complex (or cytochrome c reductase) cataly- 
ses the oxidation of ubiquinol by cytochrome c coupled 
to a vectorial translocation of protons across the mito- 
chondrial inner membrane [11. In Succharomyces cerevis- 
iue, it consists of at least ten different polypeptide 
subunits, three of which carry redox prosthetic groups: 
cytochrome b, cytochrome cI and the Rieske iron sulfur 
protein [2]. The cytochrome b plays a central role in the 
energy-transducing activity of the bc, complex by trans- 
ferring electrons through the membrane from an electro- 
positive ubiquinol oxidation proton ejector (QJ site to 
an electronegative ubiquinone reduction proton acceptor 
(Q4 site [31. 
Extensive mutational studies have allowed the identifi- 
cation of the axial ligands of the cytochrome b hemes and 
of several residues which are important for the function 
of the cytochrome bc, complex [4-81. However, it should 
be noted that most of the mutations identified up to now 
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affect the QP site whereas only a few mutations modify- 
ing the QN site have been found. Much information has 
been gained on the structural characteristics of the ubiq- 
uinol oxidation site but little is known on the quinone 
reduction site. We report here the isolation and charac- 
terization of four different functionally modified cyto- 
chrome b mutants carrying a single amino acid replace- 
ment in regions involved in the binding of antimycin, a 
QN site inhibitor. One of these mutants (G33D) was se- 
lected for the loss of the ability to grow on respiratory 
substrates. Three others (D33A, K221E and K221Q) 
were obtained as pseudo-revertants from the G33D mu- 
tant and from another respiratory deficient mutant 
(M221K) that has been described previously [9]. The 
results support the possible involvement of the G33 in 
helix packing around the hemes [lo] and suggest intra- 
molecular interactions between the N-terminal region 
and the loop connecting helices IV and V of the current 
&helix cytochrome b folding model [l l-131. 
2. Materials and methods 
2.1. Media 
YG: 1% yeast extract, 1% bactopeptone, 3% glycerol; YPGAL: 1% 
yeast extract, 1% bactopeptone, 3% galactose; YPDlO: 1% yeast ex- 
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tract, 1% bactopeptone, 10% glucose; ETOH: 1% yeast extract, 1% 
bactopeptone, 3% ethanol. Solid media contained 2% agar. 
2.2. Chemicals 
PCR, 20 ng of double stranded DNA were used. The couple P2-P3 was 
used for symmetrical amplification of DNA of the revertants from 
KM708 and the couple P4-P5 for symmetrrcal mplification of DNA 
of the revertants from KM108. 
Antimycin was purchased from Boehringer Mannheim. 
2.8. DNA Sequencing 
2.3. Strains 
The two respiratory-deficient mutants and the wild type strain are 
from the Gif Collection. The wild type, KM 91, results from the cross 
between KL14-4A (a his1 trp2 rho@) and 17%3A (a adel opl rho+) 
[14,15]. The original rho+ mitt respiratory deficient mutants, M4410 
and M7622 were isolated from the haploid strain 777-3A and carried 
the nuclear op, mutation [16]. They were crossed with KL14-4A (a his1 
trp2 OPI rho? in order to restore the nuclear genetic background 
allowing ATP/ADP translocation. The mtDNA sequence of M4410 has 
been determined by Lemesle-Meunier [9]. 
Sequencing was carried out on asymmetrical PCR products using 
Sequenase kit (USB, Cleveland, Ohio, USA) with [“S]dATP (Amer- 
sham). The respiratory deficient mutant M7622 (G33D) was sequenced 
by reverse transcription of the cytochrome b mRNA with avian myelo- 
blastosis virus reverse transcriptase (Amersham Corp.) as described by 
di Rago and Colson [21]. 
2.9. Isolation of mttochondria and growth rates determinations 
As described in [22]. 
2.10. Respiratory activities measurements 
2.4. Oligonucleotides As described by Briquet and Goffeau [23]. 
The sequence of the primers and their positions on the split cyto- 
chrome b gene (‘long version’ of the gene [17-191) are: 
Pl: 45164537: 5’-GTA TGA ATG CAT TGG AAT TCT-3’ 
P2: 5’-ATA TTT TAT AAA TAA ATA ATA ATA ATA TGG-3’ 
P3: 329-350: 5’-CCT ACA TTTCAT AAT AGT ACT C-3’ 
P4: 4383440: 5’-CCC TCT AAT CCA GAG ATT CTTTGC G-3’ 
P5: 45794604: 5’-GAA TAG AAT ACA AAT AAT GCT AAA AT-3 
3. Results 
3.1. Genetic location and sequence determination of the 
mii mutant A47622 
The position of the primers are given according to their first and last 
base pair numbers on the cytochrome b gene except for primer P2 which 
is just upstream the cytochrome b gene. 
2.5. Isolatron of revertants 
As described in [5]. 
2.6. Total DNA extraction 
Cells grown in 1 ml YPGAL overnight at 28°C were centrifuged 5 
min at 2,000 x g. The pellet was treated with a suspension containing 
400~1 0 mM Tris-HCl (PH 7.5), 1 mM EDTA, 400~1 phenol, and glass 
pearls. The suspension was shaken vigorously for 5 min and centrifuged 
for 20 min. The aqueous phase was treated with an equal volume of 
phenol, centrifuged and extracted with an equal volume of chloroform. 
The nucleic acids were ethanol precipitated and resuspended in 10 mM 
Tris-HCl pH 7.5, 1 mM EDTA. For symmetrical PCR amplification 
500 ng of total DNA were used. 
The mit- mutant M7622 was derived from a strain (see 
Section 2) possessing the long version of the split mito- 
chondrial cytochrome b gene which is 7,172 base pairs 
long and contains six exons [17-191. According to the 
cob-box physical and genetic maps, the mutation should 
be located close to the 5’ end of the cytochrome b gene 
[ 17-191. This was confirmed by sequence determination 
which revealed a unique nucleotide substitution in exon 
Bl leading to the replacement of the glycine in position 
33 (GGT) by an aspartic acid (GAT). The perfect agree- 
ment between genetic mapping and sequencing data al- 
lows us to conclude that the detected apocytochrome b 
alteration is truly responsible for the mutant phenotype. 
2.7. Symmetrical and asymmetrical PCR 
These were carried out according to McCabe [20]. For asymmetrical 
The mutant M7622 exhibited a stringent respiratory- 
deficient phenotype with total absence of growth on non- 
fermentable substrates even after prolonged incubation 
Table 1 
Summary of mtDNA sequence alterations, growth rates, respiratory activities and inhibitor sensitivities of the mit- mutants M221K and G33D and 
their revertants 
Mutation Number T, Growth Growth NADH Succinate Z,, I I I 
of (“C) rate rate oxidase oxidase antimycin gmpound gmpound gmpound 
revertants GAL ETOH activity activity (pg/ml) A B C 
(pg/ml) (pg/ml) (pg/mt) 
Wild type - 
M221-K - 
M221-Q 8 
M221-E 48 
G33-D - 
G33-A 1 
58 1 1 100 100 180 1.9 5.6 76 
55 - - 0 0 - - 
49 1 1.2 61 95 480 1.2 12.8 226 
49 1.1 1.1 80 100 500 5.3 20 180 
- - - 0 0 - - - - 
- 1 1 63 100 170 3.9 26 207 
The mtDNA sequence of mutant M221K was determined by Lemesle-Meunier et al. [9]. NADH and succinate oxidase activities were assayed from 
mitochondria at 28°C in a Clark electrode and are expressed relative to the wild type KM91 (NADH and succinate activities were respectively 196 
and 14 nmol0,. min-‘. mg-’ for strain KM91). The presence of a secondary mutation near the original mutated site was detected by oligonucleotide 
hybridization [5]. The fusion temperatures for the wild type, the respiratory deficient mutant M221K and its revertants are indicated under T, (melting 
temperature (“C)). Growth in galactose (YPGAL) and ethanol (ETOH) media is expressed as the ratio of the mutant’s growth rate in exponential 
phase relative to that of the wild type. The I,, values are the inhibitor concentrations (in pg/ml) required to reduce by 50% the NADH oxidase 
activity. 
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Fig. 1. Cytochrome absorption spectra of whole cells from the wild type (KM91), the respiratory deficient mutant G33D and its pseudo revertant. 
The spectra were recorded from whole cells at liquid nitrogen temperature after reduction of cytochromes by dithionite. Arrows indicate the positions 
of the a band absorption maxima of cytochrome c, cytochrome e, and cytochromes u and uY 
periods (up to three weeks). Spectral analysis of whole 
cells grown on galactose revealed the complete absence 
of dithionite-reducible cytochrome b whereas cyto- 
chrome c and au, were clearly detectable (Fig. 1). Mito- 
chondria extracted from the mutant were devoid of 
NADH and succinate oxidase activities. 
3.2. Isolation and characterization of revertants from the 
mutants Al4410 (M221K) and M7622 (G33D) 
The mutant M4410 has been shown to be the result of 
a single mutation at codon 22 1 (M22 1 K/ATG-AAG) [9]. 
This mutation gives an assembled but inactive bc, com- 
plex resulting in total lack of growth on non-fe~entable 
carbon sources. A total of 92 spontaneous revertants 
were selected (the revertant frequency was estimated to 
be 5*10-*). The true wild type revertants were screened 
out by tem~rature sensitive hyb~dization with primer 
PI as described in [S]. As a result, 36 appeared to be true 
wild type revertants having the same melting tempera- 
ture as the wild type (i.e. 58’C), 56 showed a lower 
melting temperature than the respiratory deficient mu- 
tant (i.e. 49°C) and therefore were supposed to carry a 
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Fig. 2. Chemical structure of natural antimycin and synthetic deriva- 
tives. The structure of natural antimycin A was illustrated taking an- 
timycin A3 as an example. Compounds A, B and C correspond to 
compounds 17, 7 and 6, respectively, m [25]. 
reversion in the close vicinity of the deficient mutation 
(Table 1). All the pseudo-wild type revertants were se- 
quenced as described in Section 2. DNA amplification 
was first carried out on total DNA using primers P4 and 
PS. The amplified double stranded DNA was used for 
asymmetrical PCR amplification using only primer P4. 
The resulting single stranded DNA was sequenced by the 
chain termination method using primer P5 as template. 
The sequence results are presented in Table 1. Most of 
the revertants (48 revertants) carried E (GAG) and 8 
revertants Q (CAG) instead of K (AAG) in position 221. 
These revertants showed growth on respiratory sub- 
strates which is comparable to that of the wild type; also 
they exhibited normal succinate respiration and only 
slightly reduced NADH oxidase activity (Table 1). 
A total of 85 genetically independent revertants were 
selected from the mutant G33D (the revertant frequency 
was estimated to be 5*10-7). All the revertants from this 
mutant were sequenced with primer P3 (after the sym- 
metrical PCR amplification with the primers P2-P3 and 
the asymmetrical amplification with P2). The sequencing 
revelaed that all the revertants were true wild type rever- 
tants except three which replaced D (GAT) in position 
33 by A (GCT). These revertants exhibited a significantly 
reduced NADH oxidase activity but grew on respiratory 
carbon sources (glycerol and ethanol) at the same rate as 
the wild type (see Table 1). Spectral analysis of these 
revertants revealed a significant reduction of cytochrome 
b whereas cytochromes c and aa, were not affected (Fig. 
1). 
We tested the in vitro resistance of each revertant to 
natural antimycin and three synthetic antimycin deriva- 
tives (compounds A-C) which possess the natural sali- 
cylic acid but not the dilactone ring structure (Fig. 2). 
These synthetic inhibitors have been shown to be good 
mimics of natural antimycin [25]. The I,, values (defined 
as the inhibitor concentration allowing 50% of the con- 
trol respiratory activity) are shown in Table 1. The rever- 
tants carrying the substitution K221E or K221Q were 
resistant o all the inhibitors tested. On the other hand, 
the revertant possessing A instead of G in position 33 
was specifically resistant to the three antimycin deriva- 
tives but sensitive to antimycin. 
4. Discussion 
Four different cytochrome b mutants with amino acid 
changes in positions 33 (G33D and G33A) and 221 
(M221Q and M221E) were isolated and characterized. 
The mutant G33D screened for respiratory deficiency 
was found to lack NADH and succinate oxidase activi- 
ties and was devoid of spectrally detectable cytochrome 
b. The characterization of revertants selected from this 
mutant led to the identification of a pseudo-reversion 
corresponding to the replacement of the G33 by A. No 
other pseudo-reversions were found although a large 
number of revertants were anlaysed. Thus only a small 
size residue such as alanine seems to be tolerated at 
position 33. According to the present cytochrome b fold- 
ing model, the G33 is buried in the membrane near the 
N-terminal end of the transmembrane helix I. In recent 
compilations of about 800 cytochrome b sequences from 
various origins, it appeared that the G33 has been per- 
fectly conserved during evolution indicating important 
steric constraints for the position 33 [26]. 
Three other glycine residues located in the bilayer are 
also perfectly conserved. These are G117 and G131 in 
helix III and G47 in helix I. The respiratory deficient 
mutation G13 1 S prevents the assembly of cytochrome b 
[27]. Given to its location close to the heme b565, it was 
proposed that the G131 is important for helix packing 
around the hemes [6]. This has been further substantiated 
by the observation that the 4 conserved glycines in he- 
lices I and III are spaced by 13 residues similarly to the 
4 heme liganding histidines in helices II and IV [lo]. The 
present work gives experimental arguments that the G33 
is indeed necessary for heme packing. The addition of a 
single methyl group in position 33 leads to substantial 
decrease in cytochrome b content and the bulkier aspar- 
tic acid leads to complete absence of heme incorporation 
into the apocytochrome b (Fig. 1). 
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Fig. 3. Helical wheel representation of the trans-membrane LIhelices I, II, III and IV of cytochrome b. The numbers indicate the position of amino 
acids in the yeast cytochrome b sequence. The histidines involved in the binding of the two haems of cytochrome b are surrounded by squares and 
the four invariant glycines by circles. The M221 is indicated by an arrow. 
The NADH and succinate oxidase activities are nearly 
totally abolished when the non-polar M221 is replaced 
by the positively charged lysine [9]_ Also the antimycin- 
binding site is lost. Restoration of the wild type pheno- 
type is obtained when the K221 is replaced by the nega- 
tively charged E or by Q. Therefore the respiratory 
deficiency. observed in M221 K might be due to the pres- 
ence of a positive charge. According to the current cyto- 
chrome b folding model, the position 221 is located on 
the electronegative side of the mitochond~al inner mem- 
brane, in the loop linking helices IV and V, M221 is not 
conserved among species [26]. It is present in Saccharo- 
myces cerevisiae and Schizosaccharomyces pombe but is 
replaced by Phe in all other organisms (except maize 
where serine is found). 
Since the two deficiency mutations are close to muta- 
tions conferring resistance to antimy~in and dim-on (in 
positions 31 and 225 (for the diuron resistance) and in 
position 228 (for the antimycin resistance)), it was deter- 
mined whether our new alterations also confer resistance 
to antimycin and its derivatives. The natural salicylic 
acid moiety (hydroxy group in position 2 and formylam- 
ino group in position 3) is supposed to be essential to the 
inhibitory activity [28]. In contrast, the natural dilactone 
ring structure is not essential [25]. This moiety might 
regulate close fitting of the salicylic acid moiety to the 
binding site not only by increasing the hydrophobicity of 
the molecule but also by some steric factors [25,29]. 
Three synthetic antimycin derivatives used in this study 
have been shown to be good mimics of natural antimycin 
[25]. One could assume that the salicylic acid moiety of 
these inhibitors interacts to the binding site in the same 
manner to that of naturaf antimycin. 
Irrespective of wide structural variations in the dilac- 
tone ring moiety, the reversions K22 1 E and K22 1 Q con- 
ferred resistance to both natural and synthetic antimycin 
derivatives (Table 1). It is therefore likely that the region 
surrounding position 221 interacts to the salicylic acid 
moiety of antimycin. The reversions K221 E and K221Q 
also conferred resistance to diuron (data not shown), in 
accordance to the previous results [21,30]. The revertant 
D33A was specifically resistant o all synthetic antimycin 
derivatives, but not to natural antimycin. These results 
suggest hat while position 33 is not directly involved in 
the interaction with the dilactone ring of natural antimy- 
tin, it interacts with the portion corresponding to dilac- 
tone ring moiety of synthetic inhibitors. 
A tentative topology of the N-terminal part of cyto- 
6 
chrome b and of the loop linking the tram-membrane a
helices IV and V relative to the catalytic core of the 
protein described by Tron et al. [lo] is proposed in Fig. 
3. We have taken into account the following observa- 
tions: 
(i) mutations conferring specific resistance to HQNO 
and funiculosin have been identified in positions 232 in 
mouse 1321 and 198 in yeast 1331. Reversions from respi- 
ratory deficiency mutations in 204 and 206 have been 
identified in positions 204, 205, 206 and 208 [34]. They 
confer resistance to funiculosin and to HQNO (for posi- 
tion 208) (Brasseur, G., and Brivet-Chevillotte, P., per- 
sonal communication) and would therefore be located 
close to positions 198 and 232. The association of these 
amino acids would also bring together positions 202,206 
and 229 which could be implicated in proton conduction 
at the QN site [31]. 
(ii) We can also bring together positions 17 and 225 
(where mutations conferring specific resistance to diuron 
have been identified [21,30]) as well as positions 37 and 
228 (where mutations conferring specific resistance to 
antimycin have been identified [21]). 
(iii) The positions 30 and 206 should also be relatively 
proximal since a respiratory deficient mutation in 206 
can be compensated by a reversion in 30 [34]. 
(iv) Positions 31 and 221 could be close to each other 
because these are the only positions where mutations 
confer resistance both to antimycin (and to its three de- 
rivatives) and to diuron. These positions should be lo- 
cated near the catalytic core of the protein. 
Amino acid changes affecting inhibitor resistance at 
center N were identified not only among mutants which 
have been selected for inhibitor resistance but also 
among revertants of deficient mutants. It is noteworthy 
that a double nucleotide change of the wild type sequence 
would be necessary to obtain the mutations in the rever- 
tams. This probably explains why these alterations have 
not been identified during the characterization of the 
inhibitor resistant mutants. Interestingly, these positions 
are clustered within the two predicted center N sub- 
regions which involve the loop between helices IV and 
V and the N-terminal end of helix I at the inner side of 
the mitochondrial inner membrane. 
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